Detalhe da pesquisa
1.
Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water Labeling.
Clin Infect Dis
; 69(3): 542-545, 2019 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30590481
2.
Development of an HIV-1 integrase genotyping assay for HIV-1 subtype AE.
J Med Virol
; 91(5): 890-893, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30548936
3.
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30038044
4.
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Gut
; 66(11): 2013-2023, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27534671
5.
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
J Hepatol
; 66(1): 11-18, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27545497
6.
Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.
BMC Bioinformatics
; 17 Suppl 8: 280, 2016 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27587008
7.
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
HIV Clin Trials
; 17(2): 78-87, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26892863
8.
Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.
J Hepatol
; 62(5): 1033-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25514556
9.
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
Hepatology
; 59(2): 434-42, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23939953
10.
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
Liver Int
; 35(2): 422-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25277773
11.
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.
Dig Dis Sci
; 60(1): 260-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25179493
12.
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.
Dig Dis Sci
; 60(5): 1457-64, 2015 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25532501
13.
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
J Hepatol
; 60(4): 715-22, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295873
14.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
Lancet
; 381(9865): 468-75, 2013 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23234725
15.
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Clin Gastroenterol Hepatol
; 12(12): 2106-12.e1, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24929235
16.
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
J Med Virol
; 86(9): 1473-81, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24861361
17.
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
Hepatology
; 58(2): 505-13, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23364953
18.
HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.
Liver Int
; 34(7): 1025-32, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24118725
19.
Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection.
J Virol Methods
; 311: 114640, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332714
20.
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Antimicrob Agents Chemother
; 53(3): 1116-23, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19075055